Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2001

View Archived Issues

Elan reports advances in product portfolio in first quarter

Senetek's Invicorp well tolerated for ED in hypertensive patients

Continuing success of double transplant procedure demonstrated by BioTransplant and MGH

Donepezil highlighted at Progress in Alzheimer's and Parkinson's Disease meeting

Antigenics to acquire Aronex; broadens product portfolio

PowderJect's hepatitis B DNA vaccine elicits high immunogenicity in nonresponders

Animal studies support potential of KW-6002 in PD, both alone and with dopaminergic drugs

New safety and efficacy data submitted to support anakinra BLA

Genentech highlights Q1 2001 progress

Active Biotech successfully completes phase I trial of SAIK-MS compound

In vitro data described in Stuttgart for Slovakofarma's investigational ACAT inhibitor

m-phasys enters three important drug discovery alliances

Starpharma develops second-generation antiviral dendrimers for STDs

New series of human HIV-1 RT inhibitors presented at Antiviral Research conference

Modex Therapeutics progresses in phase II clinical evaluation of EpiDex

Nanomolar anti-HIV activity discovered in new series of reverse transcriptase inhibitors

TNFerade expected to have wide safety margin in humans based on murine data

Intranasal proteosome influenza vaccine shows positive safety and tolerability profile in humans

Prodrug of beta-L-dC with improved oral bioavailability and systemic delivery

Temporary suspension of phase II trials of INS-365 in bronchitis announced

HGS discovers new human protein termed PGRP-L

Novel polypeptide and use in diagnosis, treatment of cancer

New beta-lactamase inhibitors in development at GSK for use in Rx of bacterial infections

Recent patent covers new selective beta3-adrenoceptor agonists synthesized at Sanofi-Synthelabo

Abbott discloses sulfonylphenylpyrazole COX-2 inhibitors

PPAR modulators discovered as part of Lilly/Ligand collaboration

NPS presents new calcium receptor modulators and their use

Identification of selective Y5 receptor antagonists described by Synaptic team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.